Distribution of peptidases in cultured cells from middle ear mucosa: prolyl endopeptidase is localized in fibroblasts and dipeptidyl peptidase IV and II in epithelial cells

Dipeptidyl peptidase II (DPPII), a review

An increasing number of biological processes appear to be regulated by Pro-specific N-terminal processing. The proline-specific dipeptidyl peptidases (DPPs) like DPPIV, fibroblast activation protein alpha (FAP), DPPII, DPP8 and DPP9, because of their preference for cleavage after X-Pro in vitro, are likely to be involved in many of these processes. These DPPs are emerging as an important protease family with roles in the regulation of signaling by peptide hormones. Dipeptidyl peptidase II (DPPII, E.C. 3.4.14.2) is an intracellular protease that localizes to the vesicular system. It releases, preferably at acidic pH, N-terminal dipeptides from oligopeptides with Pro or Ala in the penultimate position. Despite the fact that the physiological role of DPPII still has not been elucidated, several suggestions were made on possible functions of the enzyme depending on its localization in different cells, body fluids and organs. DPPII was a.o. suggested to be involved in the processes of cell differentiation and in the protection from cell death, and to have a role in the degradation of collagen fragments, myofibrillar proteins and short neuropeptides. Moreover, changes in the level and distribution of the enzyme provided clues indicating additional roles in disease-related processes. Here we review the DPPII literature, aiming to bring more clarity in the disperse data on this subject and give a state of the art on DPPII research.

Evidence for the presence of prolyl oligopeptidase and its endogenous inhibitor in neonatal rat pancreatic beta-cells

Prolyl oligopeptidase (PE), an enzyme that may be involved in the maturation and degradation of hormones and neuropeptides has been detected in neonatal rat pancreatic islet cell monolayer cultures. PE activity was not observed in islet cell homogenates but when cellular extracts were subjected to gel-filtration, a such activity with a molecular mass about 70 kDa can be detected. Gel-filtration experiment has led to the finding of a PE inhibitor in these extracts with an estimated molecular mass of 6.5 kDa. After separation of the endogenous inhibitor from PE enzyme by gel-filtration, PE inhibitor was partially purified in a single activity peak by reverse-phase high-performance liquid chromatography (HPLC). It inhibited the fluorogenic substrate Z-Gly-Pro-beta Na degradation by partially purified PE in a competitive manner. Inhibitor is shown to be specific for PE enzyme and it is not released by potassium depolarization of islet cell membrane. These findings indicated that inhibitor is localized in the cytosolic compartment as prolyl oligopeptidase. The specific activity of the inhibitor in beta-cell cultures derived from donor rats varying from 3-20 days of age was unchanged. In contrast, PE inhibitor can only be detected in pancreatic tissue from 3-day-old rats compared with tissue from 20-day-old and adult rats after gel filtration. This discrepancy can be relevant to the different endocrine/exocrine tissue ratios in the pancreas during developing rats. Furthermore, pancreatic tissue from streptozotocin-treated 3-day-old rats did not show PE inhibitory activity indicating that PE inhibitor was principally contained in beta-cells. Based on the biochemical characteristics of the beta-cell PE inhibitor, the enhancement of PE activity observed in neonatal pancreas of STZ-treated rat as previously described (P. Salers, Regul. Pept., 50 (1994) 101-111), appears to be due to the presence of the endogenous PE inhibitor in neonatal rat pancreatic beta-cells that disappears following STZ-treatment.